6月1日，三生制药开盘上涨5.95%，报19.6港元/股，成交额963.85万港元。消息面上，ASCO年会期间三生制药核心管线PD-1/VEGF双特异性抗体SSGJ-707两项临床研究入选大会，其中一项获快速口头报告资格。据已公布摘要，SSGJ-707单药治疗晚期NSCLC的II期研究确认ORR达67.6%，中位PFS为12.4个月；联合化疗一线治疗子宫内膜癌确认ORR分别为85.7%和80.0%，数据表现亮眼。同期生物科技板块整体偏强，科伦博泰生物涨5.37%、百济神州涨1.3%，板块共振进一步提振市场情绪。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.